Condition: Pertussis · Sponsor: Mahidol University
This is a phase IV, open-label, non-randomized study to demonstrate superior immunogenicity and safety of a second booster dose of Pertagen® as compared to Adacel® at 10 years after the first booster vaccination and to evaluate the long-term persistence of specific antibodies induced by BioNet's recombinant aP (Pertagen®) and TdaP (Boostagen®) vaccines and a chemically-detoxified Tdap vaccine (Adacel®) at 10 years after the first booster in participants who were vaccinated in the phase II/III trial (Protocol No. TDA202).
This description comes directly from the study's public registry record.
Punnee Pitisuttithum · 0818294906 · punnee.pit@mahidol.ac.th
Jittima Dhitavat · 0875921777 · ่jittima_pu@yahoo.com
Always discuss trial participation with your own doctor first.
| Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University | Bangkok Noi, Bangkok Metropolis, Thailand | Recruiting |
| Vaccine Trial Centre | Ratchathewi, Bangkok Metropolis, Thailand | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06803524